GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sagent Pharmaceuticals Inc (NAS:SGNT) » Definitions » Operating Margin %

Sagent Pharmaceuticals (Sagent Pharmaceuticals) Operating Margin % : -0.65% (As of Jun. 2016)


View and export this data going back to 2011. Start your Free Trial

What is Sagent Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Sagent Pharmaceuticals's Operating Income for the three months ended in Jun. 2016 was $-0.5 Mil. Sagent Pharmaceuticals's Revenue for the three months ended in Jun. 2016 was $71.7 Mil. Therefore, Sagent Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2016 was -0.65%.

The historical rank and industry rank for Sagent Pharmaceuticals's Operating Margin % or its related term are showing as below:


SGNT's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.355
* Ranked among companies with meaningful Operating Margin % only.

Sagent Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Sagent Pharmaceuticals's Operating Income for the three months ended in Jun. 2016 was $-0.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2016 was $-53.2 Mil.


Sagent Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Sagent Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagent Pharmaceuticals Operating Margin % Chart

Sagent Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Operating Margin %
Get a 7-Day Free Trial -14.22 -8.44 12.82 6.59 -13.99

Sagent Pharmaceuticals Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 2.32 -56.87 -10.65 -0.65

Competitive Comparison of Sagent Pharmaceuticals's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Sagent Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagent Pharmaceuticals's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sagent Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Sagent Pharmaceuticals's Operating Margin % falls into.



Sagent Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Sagent Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2015 is calculated as

Operating Margin %=Operating Income (A: Dec. 2015 ) / Revenue (A: Dec. 2015 )
=-44.521 / 318.296
=-13.99 %

Sagent Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2016 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2016 ) / Revenue (Q: Jun. 2016 )
=-0.469 / 71.721
=-0.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sagent Pharmaceuticals  (NAS:SGNT) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Sagent Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Sagent Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagent Pharmaceuticals (Sagent Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sagent Pharmaceuticals Inc is a Delaware corporation that was incorporated in 2011. The Company was initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, it reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with its initial public offering, on April 26, 2011. The Company is engaged in the developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily in the United States of America. The Company primarily focuses on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, it offers customers, products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. It generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. At the year end, the Company's product portfolio has grown to a total of 53 products which can be classified into the following three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. The Company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by a wide variety of end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. The Company's principal competitors include Fresenius Kabi, a division of Fresenius SE, Hospira, Inc., Pfizer Inc., Sandoz International GmbH, a division of Novartis AG, Teva Pharmaceutical Industries Ltd. and West-Ward Pharmaceutical Corp. The Company is subject to extensive regulation by governmental authorities in the U.S. and in other countries.
Executives
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Vivo Ventures V, Llc 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Vivo Ventures V Affiliates Fund, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALO ALTO CA 94301
Vivo Ventures Fund V, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Jonathon M Singer officer: EVP and CFO 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Michael Fekete director C/O SAGENT PHARMACEUTICALS, INC., 1901 NORTH ROSELLE ROAD, SUITE 700, SCHAUMBURG IL 60195
Robert J Flanagan director C/O SAGENT PHARMACEUTICALS, INC., 1901 NORTH ROSELLE ROAD, SUITE 700, SCHAUMBURG IL 60195
Sean Brynjelsen officer: EVP, Business Development C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
Vivo Ventures Vi Affiilates Fund, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALP ALTO CALIFORNIA CA 94301
Vivo Ventures Fund Vi, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALO ALTO CA 94301
Vivo Ventures Vi, Llc 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Frank Kung director C/O VIVO CAPITAL, 505, PALO ALTO CA 94301
Jeffrey Yordon director
Morgan Stanley Investment Management Inc 10 percent owner 1221 AVENUE OF AMERICAS, NEW YORK NY 10020
Ronald Pauli officer: Chief Financial Officer 2730 WILSHIRE BLVD., #500, LOS ANGELES CA 90403

Sagent Pharmaceuticals (Sagent Pharmaceuticals) Headlines

No Headlines